BofA Global Research initiates coverage of Viridian Therapeutics with buy rating; price objective $47
VRDN•BofA Global Research initiated coverage of Viridian Therapeutics with a buy rating and a $47 price objective.
Related News

UBS raises Unum Group target price to $111 from $94
UNM•

Abbott initiates Voyager clinical trial for investigational TAVI system
ABT•

HeartSciences signs equity distribution agreement for up to $50 million with Maxim Group
HSCS•

Sempra: Argus Research cuts target price to $98 from $105
SRE•

Gulfport Energy Corporation: UBS cuts target price to $210 from $217
GPOR•